Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. - Wikidata - wikimedia - TriplyDB

Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.

Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.

http://www.wikidata.org/entity/Q42285675

about

Therapeutic Drug Monitoring of Posaconazole: an Update Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Posaconazole salvage treatment for invasive fungal infection.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.Antifungal agents and liver toxicity: a complex interaction.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease.Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.Posaconazole in lung transplant recipients: use, tolerability, and efficacy.Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests.Posaconazole: An Update of Its Clinical Use.Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections.Posaconazole liquid vs tablet formulation in lung transplant recipients.Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis.

P2860

Q26746016-F76624C7-176D-434B-8D30-D4511A7D68C0 Q28553573-32F9F9C8-94B2-461E-9DD0-6CD3738AB942 Q34532546-511850C1-8ED9-4633-8778-C337F0BA99EF Q35732778-8A533B51-FACD-4E3C-AD00-ABFDC342D451 Q36658777-DEF54D1B-395C-4290-95E9-124987000F68 Q36933524-7A56925D-A7AD-4AD0-8C02-8BA0BA54DD22 Q37358747-14B780A2-0DCA-4587-8E6C-4076DB8A2558 Q38140015-75C718E8-3D58-43E4-85FA-3C2C2090F01C Q38237895-DB6833B1-8B02-43E2-8573-222B0B2FEFA9 Q38341595-6B617A24-EAFA-496C-94B6-76B2259DE9C8 Q38858839-3137775F-0FED-4CEB-94A9-27C3444DB794 Q38871233-D106720A-9564-48FE-B24C-B42F3304FD08 Q38890514-7B160853-0D63-4D4D-9CB4-869A87879E7E Q40062960-CF47FBA1-4DC3-4EF2-AEC0-4D9EA20CB0DF Q40225550-E8C3D83A-1356-4FDF-A44F-0239DF622F13 Q40827808-AF925544-09EB-45F8-AE58-30B99D49AF43 Q41031277-123068F1-B2CA-4505-9A7C-AFAD60697EA8 Q42144246-52899FA9-8EE1-4FA8-8BF5-24A041F15493 Q47141618-9B93697A-2F88-4027-B04E-F8B44EB5EBEC Q48354018-B48AB2C2-5496-4B46-94F3-7F1E19B3A201 Q54243380-A0AFB28A-7F37-412E-BAE7-8D95AAD2E1D2 Q54253897-0EB4FAD3-E0A8-4428-B17E-D3D9951EC98D

P2860

Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.

http://www.wikidata.org/entity/Q42285675

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Posaconazole after previous an ...... ase, a retrospective analysis.

@en

Posaconazole after previous an ...... ase, a retrospective analysis.

@nl

type

label

Posaconazole after previous an ...... ase, a retrospective analysis.

@en

Posaconazole after previous an ...... ase, a retrospective analysis.

@nl

prefLabel

Posaconazole after previous an ...... ase, a retrospective analysis.

@en

Posaconazole after previous an ...... ase, a retrospective analysis.

@nl

P1433

Q42285675-9AA70535-ACBB-4B23-9EA6-3A2E02917DFA

P1476

Q42285675-A62E51DF-CF3B-436A-B9C2-81E465FB75C4

P2093

Q42285675-3A03DE1A-59BB-4B76-8203-C2C43CD78C1A

Q42285675-C9A7C24E-8911-43B3-B431-ED289F42360C

Q42285675-E339B97A-313A-4BFA-9CC1-64E9E411B42B

Q42285675-EF98D373-8950-4357-819F-89841A38E5CD

P2860

Q42285675-15BFA630-A4CC-45F7-8E5A-DFF604463075

Q42285675-17C4467E-CACD-4141-9980-54B8B25831A1

Q42285675-1BF9A134-3A20-4AA2-98B2-34D9227F8ECF

Q42285675-2AC6741C-96F0-4143-A5FD-A1CB4B0A0780

Q42285675-39536B72-F36E-4ED0-A689-8F660EFCDBEA

Q42285675-4C98A0DC-ACAE-4229-9398-86E017CFE1A6

Q42285675-4FE00E8E-8FE0-4EC5-9AD5-B8C7493A2265

Q42285675-63ADBC00-141B-4AB1-B4F5-13DB7E41CA83

Q42285675-66520103-04F8-4688-AAE6-FA808038E4DF

Q42285675-B1D6EB41-C788-4DE7-95F8-8A6038D87930

P304

Q42285675-D9A07274-906A-4F6E-A730-0C67C8CFEA1E

P31

Q42285675-65ED9353-E83A-4554-9498-40B60F3E5E71

P356

Q42285675-F6BFA325-08AA-4374-8349-A0DA5658EDB3

P433

Q42285675-23B111E8-AD29-4B75-8955-1300BFBCA0F8

P478

Q42285675-125EED3C-FA5F-491D-BE4C-E3494DB9C387

P50

Q42285675-833160B4-F705-4A58-819F-F289CF08AEB8

P577

Q42285675-BE76C679-0600-4DA8-B246-3BD4BEACC4E9

P698

Q42285675-A9E3D94D-F5AB-4F63-A00D-63B948841BA0

P356

P1433

P1476

Posaconazole after previous an ...... ease, a retrospective analysis

@en

P2093

Angelika Boehme

http://www.w3.org/2001/XMLSchema#string

Gerlinde Egerer

http://www.w3.org/2001/XMLSchema#string

Heinrich Lellek

http://www.w3.org/2001/XMLSchema#string

Jochen Greiner

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

The changing face of epidemiology of invasive fungal disease in Europe.

New generation azole antifungals in clinical investigation.

Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

P304

304-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/MYC.12023

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23170837

http://www.w3.org/2001/XMLSchema#string